Psoriasis Management: Proactive Drug Monitoring Study

We are comparing proactive drug monitoring to standard care for people with moderate to severe psoriasis. The goal is to see if proactive monitoring helps maintain better disease control and improves quality of life.

1-2 years Monitoring phase (IV)No Placebo Standard Medicines InjectionAllergologyDermatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Cosentyx

Cosentyx is a medicine used to treat plaque psoriasis, psoriatic arthritis, and certain inflammatory spine conditions.

Taltz

Taltz is a prescription medicine used to treat moderate-to-severe plaque psoriasis and psoriatic arthritis.

Tremfya

Tremfya is a medicine used to treat moderate to severe plaque psoriasis and to help relieve symptoms of psoriatic arthritis.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Guselkumab

Guselkumab is a lab-made antibody that blocks an immune signal to reduce inflammation in people with moderate-to-severe plaque psoriasis.

Ixekizumab

Ixekizumab is a substance that targets an inflammatory protein to reduce skin inflammation in moderate-to-severe plaque psoriasis and related autoimmune conditions.

Secukinumab

Secukinumab is a substance that blocks a specific immune protein to reduce inflammation in conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Grand Hopital De Charleroi

Dermatologie

Châtelet, Belgium

Algemeen Ziekenhuis Alma

Dermatology

Eeklo, Belgium

Universitair Ziekenhuis Brussel

Dermatologie

Ganshoren, Belgium

Sponsor: Universitair Ziekenhuis Gent

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.